BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Vanrafia (Atrasentan) readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Vanrafia (Atrasentan)\, from ClinicalTria
 ls.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07820995-330@assetmemo.bio
DTSTAMP:20261121T005618Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Vanrafia (Atrasentan): Phase 4 readout est. (NCT07820995)
DESCRIPTION:Vanrafia (Atrasentan)\, phase 4\, IgA Nephropathy.\nStudy: Mech
 anistic Evaluation of Atrasentan in Patients With IgA Nephropathy (IgAN)\n
 Estimated primary completion: 31 December 2027. This is a ClinicalTrials.g
 ov estimate\, not a confirmed readout date\, and it can move.\nDrug page: 
 https://assetmemo.bio/drug/atrasentan#upcoming-events\nRegistry record: ht
 tps://clinicaltrials.gov/study/NCT07820995
URL:https://assetmemo.bio/drug/atrasentan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04573478-330@assetmemo.bio
DTSTAMP:20261121T005618Z
DTSTART;VALUE=DATE:20280414
DTEND;VALUE=DATE:20280415
SUMMARY:Vanrafia (Atrasentan): Phase 3 readout est. (NCT04573478)
DESCRIPTION:Vanrafia (Atrasentan)\, phase 3\, IgA Nephropathy.\nStudy: Atra
 sentan in Patients With IgA Nephropathy\nEstimated primary completion: 14 
 April 2028. This is a ClinicalTrials.gov estimate\, not a confirmed readou
 t date\, and it can move.\nDrug page: https://assetmemo.bio/drug/atrasenta
 n#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT04
 573478
URL:https://assetmemo.bio/drug/atrasentan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07850752-330@assetmemo.bio
DTSTAMP:20261121T005618Z
DTSTART;VALUE=DATE:20280917
DTEND;VALUE=DATE:20280918
SUMMARY:Vanrafia (Atrasentan): Phase 3 readout est. (NCT07850752)
DESCRIPTION:Vanrafia (Atrasentan)\, phase 3\, IgA Nephropathy.\nStudy: A St
 udy of the Efficacy and Safety of Zigakibart + Atrasentan in Adult Patient
 s With Primary IgA Nephropathy\nEstimated primary completion: 17 September
  2028. This is a ClinicalTrials.gov estimate\, not a confirmed readout dat
 e\, and it can move.\nDrug page: https://assetmemo.bio/drug/atrasentan#upc
 oming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0785075
 2
URL:https://assetmemo.bio/drug/atrasentan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07498335-330@assetmemo.bio
DTSTAMP:20261121T005618Z
DTSTART;VALUE=DATE:20310915
DTEND;VALUE=DATE:20310916
SUMMARY:Vanrafia (Atrasentan): Phase 3 readout est. (NCT07498335)
DESCRIPTION:Vanrafia (Atrasentan)\, phase 3\, IgA Nephropathy.\nStudy: Stud
 y to Assess the Efficacy\, Pharmacokinetics\, Safety and Tolerability of A
 trasentan in Pediatric Patients With Primary IgAN\nEstimated primary compl
 etion: 15 September 2031. This is a ClinicalTrials.gov estimate\, not a co
 nfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/
 drug/atrasentan#upcoming-events\nRegistry record: https://clinicaltrials.g
 ov/study/NCT07498335
URL:https://assetmemo.bio/drug/atrasentan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
